Kristina Burow has bought stock on 8 days since Oct 2019

Kristina Burow is an independent Class I director at Neumora Therapeutics, Inc. (NMRA), serving since January 2020 with her current term expiring at the 2027 annual meeting.( She chairs the Compensation Committee and serves on the Nominating & Corporate Governance Committee, previously on the Audit Committee until April 2025, and maintains strong attendance records.( As a Managing Director at ARCH Venture Partners since November 2011 (joining in 2002), she focuses on creating and developing biotechnology, pharmaceutical, and health tech companies, co-founding successes like Receptos (acquired by Celgene) and Orbital Therapeutics.(

Burow's career highlights include prior roles at Novartis BioVenture Fund and as an early employee at the Genomics Institute of the Novartis Research Foundation, directing chemistry operations and business development.( She serves on multiple public and private biotech boards, including Beam Therapeutics, Scholar Rock, Boundless Bio, and Autobahn Therapeutics, with experience across gene editing, CNS, and other modalities.( Education: B.S. in Chemistry (UC Berkeley), M.A. in Chemistry (Columbia University), M.B.A. (University of Chicago Booth).(

Written by Perplexity from public sources.